QRPH TC Tcon Agenda 2008-05-01: Difference between revisions
Jump to navigation
Jump to search
FEisenberg (talk | contribs) No edit summary |
FEisenberg (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
** [http://wiki.ihe.net/index.php?title=White_Paper:_Care_Management_Content/Infrastructure Care Management White Paper]: Due to HL7 Care Plan evaluation work required, consider making this an 18 month or 2 year white paper. | ** [http://wiki.ihe.net/index.php?title=White_Paper:_Care_Management_Content/Infrastructure Care Management White Paper]: Due to HL7 Care Plan evaluation work required, consider making this an 18 month or 2 year white paper. | ||
** [http://wiki.ihe.net/index.php?title=Drug_Safety_Content Drug Safety Profile]: Requires ICSR mapping to CDA for inclusion in the profile. Options are rapid recruitment of volunteer members for post-market surveillance activities or limitation to clinical trial reporting. Some followup planned during HL7 with FDA and others. | ** [http://wiki.ihe.net/index.php?title=Drug_Safety_Content Drug Safety Profile]: Requires ICSR mapping to CDA for inclusion in the profile. Options are rapid recruitment of volunteer members for post-market surveillance activities or limitation to clinical trial reporting. Some followup planned during HL7 with FDA and others. | ||
Link back to Technical Committee page [[Quality%2C_Research_and_Public_Health_Technical_Committee]] | |||
Revision as of 08:53, 1 May 2008
1 May 2008 Agenda for QRPH Technical Committee Conferenc Call
- Call to order
- Attendance
- Update on status of three planned initiatives April_29_-_QRPH_Planning_Discussion:
- Performance Measure Data Element Structured for EHR Extraction White PaperCurrent version 26 April
- Care Management White Paper: Due to HL7 Care Plan evaluation work required, consider making this an 18 month or 2 year white paper.
- Drug Safety Profile: Requires ICSR mapping to CDA for inclusion in the profile. Options are rapid recruitment of volunteer members for post-market surveillance activities or limitation to clinical trial reporting. Some followup planned during HL7 with FDA and others.
Link back to Technical Committee page Quality,_Research_and_Public_Health_Technical_Committee